9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Summary

This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or metastatic urothelial cancer.

Eligibility

Inclusion Criteria:

* Sign and date the informed consent form e approved by independent ethics committe.
* Male or female subjects aged 18 to 80 years (including 18 and 80 years).
* ECOG status of 0 or 1.
* Histologically or cytologically confirmed local advanced or metastatic urothelial cancer
* Subjects have received at least 1 line advanced standard therapy or were not treated before
* Subjects must submit tumor tissues for test
* Life expectancy of ≥ 12 weeks.
* Subjects must have measurable lesions according to RECIST (version 1.1).
* Adequate organ functions
* Sexually active fertile subjects, and their partners, must agree to use methods of contraception during the study and at least 6 months after termination of study therapy.
* Subjects are willing to follow study procedures.

Exclusion Criteria:

* Anti-tumor treatment such as chemotherapy and radiotherapy within 21 days prior to the first dose of study drug.
* Major surgery within 28 days prior to first dose of study drug.
* PD-1/PD-L1/PD-L2 inhibitors used in the previous treatment for La/m UC.
* Previous treatment with ADCs conjugated with MMAE payload.
* Clinical significantly toxicity Grade ≥ 2 (except alopecia and pigmentation) related to previous treatment.
* Peripheral neuropathy Grade ≥ 2.
* Poorly controlled blood sugar.
* Increased risks of corneal disease assessed by the investigator prior to the first dose of study drug.
* Documented history of clinically significant cardiac or cerebrovascular diseases within 6 months prior to the first dose of study drug.
* Active infections, such as uncontrolled HBV/HCV/HIV/TB infection, etc.
* Other serious or uncontrolled diseases, such as serious interstitial pneumonia/asthma, serious thromboembolic events, etc.
* Poorly controlled central nervous system metastases.
* Organ transplantation or allogeneic hematopoietic stem cell transplantation in the past.
* History of drug abuse or mental illness.
* Known allergic sensitivity to any of the ingredients of the study drug.
* Any P-glycoprotein (P-gp) inducers/inhibitors or potent CYP3A4 inducers/inhibitors within 14 days prior to the first dose of study drug.
* History of autoimmune disease requiring systemic treatment within 2 years before the first dose.
* Any live vaccines within 4 weeks before first dose of study drug or during the study.
* Use of any investigational drug or medical instruments within 28 days prior to the first dose of study drug.
* History of another malignancy within 3 years before the first dose of study drug. Subjects with curable malignancies are allowed.
* Other conditions unsuitable into the study.

Conditions2

Browse More Trials